Journal article icon

Journal article

Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour?

Abstract:

UNLABELLED: Glucokinase activators (GKAs) represent one of the leading hopes for the next generation of type 2 diabetes (T2D) therapeutics, showing efficacy in reducing blood glucose and HbA1c levels in animal models of T2D and short-term human trials. While the hypoglycaemic risks of GCK activation in pancreatic beta-cells have long been appreciated, the hepatic effects of GKAs have generally been perceived to be without significant side effect. In this issue of the British Journal of Pharma...

Expand abstract

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, OCDEM
Journal:
British journal of pharmacology
Volume:
168
Issue:
2
Pages:
335-338
Publication date:
2013-01-05
DOI:
EISSN:
1476-5381
ISSN:
0007-1188
URN:
uuid:01fa2bae-fa99-4a6a-bd40-e98e924611d1
Source identifiers:
350477
Local pid:
pubs:350477

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP